Intracoronary injection of autologous CD34+ cells improves one-year left ventricular systolic function in patients with diffuse coronary artery disease and preserved cardiac performance-a randomized, open-label, controlled phase ii clinical trial

Pei Hsun Sung, Yi Chen Li, Mel S. Lee, Hao Yi Hsiao, Ming Chun Ma, Sung Nan Pei, Hsin Ju Chiang, Fan Yen Lee, Hon Kan Yip*

*此作品的通信作者

研究成果: 期刊稿件文章同行評審

7 引文 斯高帕斯(Scopus)

摘要

This phase II randomized controlled trial tested whether intracoronary autologous CD34+ cell therapy could further improve left ventricular (LV) systolic function in patients with diffuse coronary artery disease (CAD) with relatively preserved LV ejection fraction (defined as LVEF >40%) unsuitable for coronary intervention. Between December 2013 and November 2017, 60 consecutive patients were randomly allocated into group 1 (CD34+ cells, 3.0 × 107/vessel/n = 30) and group 2 (optimal medical therapy; n = 30). All patients were followed for one year, and preclinical and clinical parameters were compared between two groups. Three-dimensional echocardiography demonstrated no significant difference in LVEF between groups 1 and 2 (54.9% vs. 51.0%, respectively, p = 0.295) at 12 months. However, compared with baseline, 12-month LVEF was significantly increased in group 1 (p < 0.001) but not in group 2 (p = 0.297). From baseline, there were gradual increases in LVEF in group 1 compared to those in group 2 at 1-month, 3-months, 6-months and 12 months (+1.6%, +2.2%, +2.9% and +4.6% in the group 1 vs. -1.6%, -1.5%, -1.4% and -0.9% in the group 2; all p < 0.05). Additionally, one-year angiogenesis (2.8 ± 0.9 vs. 1.3 ± 1.1), angina (0.4 ± 0.8 vs. 1.8 ± 0.9) and HF (0.7 ± 0.8 vs. 1.8 ± 0.6) scores were significantly improved in group 1 compared to those in group 2 (all p < 0.001). In conclusion, autologous CD34+ cell therapy gradually and effectively improved LV systolic function in patients with diffuse CAD and preserved LVEF who were non-candidates for coronary intervention (Trial registration: ISRCTN26002902 on the website of ISRCTN registry).

原文英語
文章編號1043
期刊Journal of Clinical Medicine
9
發行號4
DOIs
出版狀態已出版 - 04 2020
對外發佈

文獻附註

Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.

指紋

深入研究「Intracoronary injection of autologous CD34+ cells improves one-year left ventricular systolic function in patients with diffuse coronary artery disease and preserved cardiac performance-a randomized, open-label, controlled phase ii clinical trial」主題。共同形成了獨特的指紋。

引用此